Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males
NCT ID: NCT03541395
Last Updated: 2018-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2015-03-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
NCT01378299
Diurnal Testosterone Concentration
NCT03091296
Calciotropic Effects After HCG Stimulation Test
NCT03254641
Safety of Testosterone Undecanoate i.m. in Hypogonadal Men
NCT00452322
Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men
NCT00700024
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Testosterone
A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.
GnRH antagonist
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GnRH antagonist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
30 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lund University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Johan Malm
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johan Malm, MD
Role: STUDY_CHAIR
Lund University
Roger Appelqvist, PhD
Role: PRINCIPAL_INVESTIGATOR
Lund University
Gyorgy Marko-Varga, PhD
Role: PRINCIPAL_INVESTIGATOR
Lund University
Aleksander Giwercman, MD
Role: PRINCIPAL_INVESTIGATOR
Lund University
Barbara Sahlin, MSc
Role: PRINCIPAL_INVESTIGATOR
Lund University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TP 001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.